Group 1 - Tmall's 618 event has seen a significant increase in overseas brand participation, with nearly 50,000 new products launched on Tmall International [1][3] - The first hour of sales recorded a doubling in transactions for 374 overseas brands, with 109 brands exceeding 10 million in sales during the initial phase [3] - New Zealand's A2 milk brand experienced a 55% increase in sales during the first phase, prompting an early arrival of 100,000 units of popular stock [3] Group 2 - The second-generation red light mask sales increased by 198% compared to last year's Double 11 event, leading to a 20% increase in stock for CurrentBody [4] - KAGAMI, a Japanese whiskey glass brand, reported a 30% increase in sales by May 27, with stock levels for 618 being more than double that of the previous year [4] - VAPE, a mosquito repellent brand, achieved the top sales in the mosquito liquid category on Tmall International, with stock levels also doubling compared to last year [4] Group 3 - Many overseas brands attribute their sales success to simplified discount mechanisms and transparent pricing during the 618 event [6] - Gotukola, an Israeli hair care brand, anticipates a 268% increase in sales, with a target of 27 million [6] - WHC, a Belgian fish oil brand, aims for 130 million in sales, reflecting a 97% year-on-year growth, aided by a 15% official discount [6] Group 4 - On June 3, Tmall's 618 Import Day featured over 1,500 global buyers conducting live streams from 15 countries, showcasing nearly 20,000 imported products at discounted prices [8] - Major discounts were offered on luxury items, such as Louis Vuitton and Coach products, with significant price reductions during the live streams [8] - Tmall International introduced various import category coupons, providing discounts up to 420 yuan for purchases over specified amounts [9]

拟6亿投建研发生产基地 润本股份于2023年10月上市，主要从事个人护理类、驱蚊类产品的研发、生产和销售，目前已形成婴童护理产 品、驱蚊产品、精油产品三大核心产品系列。 5月6日晚间，润本股份发布的公告显示，公司拟在广州市黄埔区中新广州知识城国际生物医药创新园投建新的产 研基地(投资标的名称：润本生物技术研发生产基地项目)，持续巩固公司的C2M供应链壁垒，满足未来持续增长 的产销研需求。 公告显示，上述项目投资金额为6亿元，建设内容主要包含办公区、研发区、生活区、生产制造区、园区配套工 程，用于开展个护用品、化妆品、医疗器械、医药制造行业相关产品的研发、生产制造及其配套服务。 实际上，在中新广州知识城国际生物医药创新园，润本股份已重金投入生产项目。 2024年，润本股份率先竞得位于中新广州知识城国际生物医药创新园，凤亨一路以北，凤亨二路以南，康联三路 以西ZSCB-E3-3地块，面积约3.2953万平方米的国有建设用地使用权，并于当年9月审议通过《关于签署投入产出 监管协议暨对外投资的议案》，同意公司以自有或自筹资金投资7亿元建设"润本智能智造未来工厂项目"。 在业绩持续提升之时，润本股份（603193）(6 ...

润本股份（603193.SH）2024 年年报&2025 年一季报点评 ➢ 风险提示：行业竞争加剧、人口出生率下降风险。 ➢ 线上渠道增长亮眼，婴童护理品类高增驱动业绩增长。分渠道来看： 1）线 上直销，实现营收 7.74 亿元，同比+24.84%；毛利率 63.07%，同比+1.24pct； 2）线上平台经销，实现营收 1.65 亿元，同比+23.38%；毛利率 55.66%，同比 +7.01pct；3）线上平台代销，实现营收 0.31 亿元，同比+4.06%；毛利率 52.09%， 同比+4.45pct；4）非平台经销商，实现营收 3.47 亿元，同比+39.64%；毛利 率 48.89%，同比+1.15pct。分产品来看：1）驱蚊系列，实现营收 4.39 亿元， 同比+35.39%；毛利率实现 54.18%，同比+3.87pct；2）婴童护理系列，实现 营收 6.90 亿元，同比+32.42%；毛利率实现 59.81%，同比+1.52pct；3）精油 系列，实现营收 1.58 亿元，同比+7.88%；毛利率实现 63.44%，同比+0.73pct； 4）其他产品，实现营收 0.30 亿元，同比-25.5 ...

Core Insights - The company achieved robust growth in 2024 and Q1 2025, with revenue increasing by 28% and net profit by 33% in 2024, and Q1 2025 revenue up by 44% and net profit by 25% [1][2] Financial Performance - In 2024, the company reported revenue of 1.318 billion yuan, a year-on-year increase of 27.61%, and a net profit of 300 million yuan, up 32.8% [2] - Q4 2024 revenue was 281 million yuan, a 34.01% increase year-on-year, while net profit decreased by 13.28% [2] - Q1 2025 revenue reached 240 million yuan, a 44% increase year-on-year, with net profit at 44 million yuan, up 24.6% [2] Product Category Performance - In 2024, the core product categories showed strong growth, with mosquito repellent revenue at 439 million yuan (up 35.39%) and baby care revenue at 690 million yuan (up 32.42%) [3] - In Q1 2025, baby care revenue surged by 65.57% to 179 million yuan, while mosquito repellent revenue increased by 10.5% [3] Profitability and Cost Structure - The overall gross margin for 2024 was 58.17%, an increase of 1.82 percentage points, with a net profit margin of 22.77% [4] - In Q1 2025, the gross margin was 57.67%, with a net profit margin of 18.41%, reflecting a decrease of 2.87 percentage points [4] Future Outlook - The company is expected to continue its growth trajectory, with projected net profits of 389 million yuan, 481 million yuan, and 583 million yuan for 2025, 2026, and 2027, respectively, representing year-on-year growth rates of 30%, 24%, and 21% [1][4]

Investment Rating - The investment rating for the company is "Buy" (maintained) with a target price of —— yuan over the next 6 months [1]. Core Insights - The company continues to experience high revenue growth, with a diversified product matrix [2]. - The revenue for 2024 is projected to be 13.2 billion yuan, representing a year-on-year growth of 27.6%, while the net profit attributable to the parent company is expected to reach 3.0 billion yuan, up 32.8% year-on-year [9]. - The company has a strong focus on the baby care and mosquito repellent segments, which are expected to show good growth potential [9][10]. Financial Performance Summary - Revenue and Profit Forecast: - 2024A: Revenue of 13.18 billion yuan, net profit of 3.00 billion yuan - 2025E: Revenue of 17.72 billion yuan, net profit of 3.92 billion yuan - 2026E: Revenue of 22.99 billion yuan, net profit of 5.05 billion yuan - 2027E: Revenue of 28.79 billion yuan, net profit of 6.36 billion yuan - Growth Rates: - Revenue growth rates are projected at 27.61% for 2024, 34.39% for 2025, 29.77% for 2026, and 25.22% for 2027 - Net profit growth rates are expected to be 32.80% for 2024, 30.52% for 2025, 28.78% for 2026, and 26.05% for 2027 [4][11]. Product and Market Analysis - The company has successfully increased the average selling price of its baby care products, with significant room for further price increases compared to competitors [9]. - The product matrix has been continuously enriched, with over 90 new or upgraded products launched in 2024, including children's sunscreen and egg yolk oil series [9]. - Online sales channels have shown rapid growth, with significant contributions from platforms like Douyin, while offline channels are also expanding [9]. Profitability Metrics - The overall gross margin for 2024 is projected at 58.2%, with a net profit margin of 22.8% [9]. - The company is expected to maintain a healthy return on equity (ROE), projected to be 14.43% in 2024, increasing to 19.19% by 2027 [4][11].

股票简称：润本股份 股票代码：603193 润本生物技术股份有限公司 Runben Biotechnology Co., Ltd. （广州经济技术开发区新庄五路 3 号） 首次公开发行股票主板上市公告书 保荐人（主承销商） 新疆乌鲁木齐市高新区（新市区）北京南路 358 号 大成国际大厦 20 楼 2004 室 二〇二三年十月十六日 特别提示 润本生物技术股份有限公司（以下简称"润本股份"、"发行人"、"本 公司"或"公司"）股票将于 2023 年 10 月 17 日在上海证券交易所主板上市。 本公司提醒投资者应充分了解股票市场风险以及本公司披露的风险因素， 在新股上市初期切忌盲目跟风"炒新"，应当审慎决策、理性投资。 2 第一节 重要声明与提示 一、重要声明与提示 本上市公告书部分表格中单项数据加总数与表格合计数可能存在微小差 异，均因计算过程中的四舍五入所形成。 二、风险提示 本公司提醒广大投资者注意首次公开发行股票（以下简称"新股"）上市 初期的投资风险，广大投资者应充分了解交易风险、理性参与新股交易。 具体而言，上市初期的风险包括但不限于以下几种： （一）涨跌幅限制放宽带来的股票交易风险 本公司及全体 ...

润本生物技术股份有限公司 Runben Biotechnology Co., Ltd. 首次公开发行股票并在主板上市 招股说明书 （注册稿） 本公司的发行申请尚需经上海证券交易所和中国证监会履行相应程序。本 招股说明书不具有据以发行股票的法律效力，仅供预先披露之用。投资者应当 保荐人（主承销商） 新疆乌鲁木齐市高新区（新市区）北京南路 358 号 （广州经济技术开发区新庄五路 3 号） 以正式公告的招股说明书作为投资决定的依据。 大成国际大厦 20 楼 2004 室 润本生物技术股份有限公司 招股说明书 发行人声明 中国证监会、交易所对本次发行所作的任何决定或意见，均不表明其对发 行人注册申请文件及所披露信息的真实性、准确性、完整性作出保证，也不表 明其对发行人的盈利能力、投资价值或者对投资者的收益作出实质性判断或保 证。任何与之相反的声明均属虚假不实陈述。 根据《证券法》规定，股票依法发行后，发行人经营与收益的变化，由发 行人自行负责；投资者自主判断发行人的投资价值，自主作出投资决策，自行 承担股票依法发行后因发行人经营与收益变化或者股票价格变动引致的投资风 险。 1-1-1 招股说明书 | > | | - ...

润本生物技术股份有限公司 Runben Biotechnology Co., Ltd. （广州经济技术开发区新庄五路 3 号） 首次公开发行股票并在主板上市 招股说明书 （注册稿） 本公司的发行申请尚需经上海证券交易所和中国证监会履行相应程序。本 招股说明书不具有据以发行股票的法律效力，仅供预先披露之用。投资者应当 以正式公告的招股说明书作为投资决定的依据。 保荐人（主承销商） 新疆乌鲁木齐市高新区（新市区）北京南路 358 号 大成国际大厦 20 楼 2004 室 | 发行股票类型： | 人民币普通股（A 股） | | --- | --- | | 发行股数： | 本次发行不超过 6,069.00 万股，占公司发行后总股本的 | | | 比例不低于 15%，本次发行股份均为公开发行的新股， | | | 公司原有股东不公开发售股份。 | | 每股面值： | 元人民币 1.00 | | 每股发行价格： | 【】元人民币 | | 预计发行日期： | 【】年【】月【】日 | | 拟上市的证券交易所和板块： | 上海证券交易所主板 | | 发行后总股本： | 不超过 40,459.3314 万股 | | 保荐人（主承销 ...

保荐人（主承销商） 润本生物技术股份有限公司 （广州经济技术开发区新庄五路 3 号） 首次公开发行股票并在主板上市 招股说明书 （申报稿） 本公司的发行申请尚需经上海证券交易所和中国证监会履行相应程序。本 招股说明书不具有据以发行股票的法律效力，仅供预先披露之用。投资者应当 以正式公告的招股说明书作为投资决定的依据。 新疆乌鲁木齐市高新区（新市区）北京南路 358 号 大成国际大厦 20 楼 2004 室 Runben Biotechnology Co., Ltd. 润本生物技术股份有限公司 招股说明书 发行人声明 中国证监会、交易所对本次发行所作的任何决定或意见，均不表明其对发 行人注册申请文件及所披露信息的真实性、准确性、完整性作出保证，也不表 明其对发行人的盈利能力、投资价值或者对投资者的收益作出实质性判断或保 证。任何与之相反的声明均属虚假不实陈述。 根据《证券法》规定，股票依法发行后，发行人经营与收益的变化，由发 行人自行负责；投资者自主判断发行人的投资价值，自主作出投资决策，自行 承担股票依法发行后因发行人经营与收益变化或者股票价格变动引致的投资风 险。 1-1-1 1-1-2 润本生物技术股份有 ...